Moderna's Post-Surge Pullback Leaves Wait Rating Intact

What happened

Moderna's stock has pulled back after a historic 5x run, but the underlying thesis remains unchanged. The August melanoma data validated the mRNA oncology platform, yet the company still generates minimal respiratory revenue and burns cash. Q2 2026 revenue was just $145 million, with H1 net loss of $2.1 billion and year-end cash guided to $4.7-$5.2 billion after a $950 million settlement. Wall Street's cooling reflects both profit-taking and the lack of near-term catalysts beyond the melanoma filing. The DeepValue report maintains a WAIT rating with an attractive entry below $115 and a trim above $170.

Implication

The current price near $140 offers limited margin of safety given the company's negative earnings and cash burn. The next six months hinge on whether Moderna submits the melanoma regulatory filing and shows progress on 2027 flu contracting. Without these, the stock could drift lower toward the bear case of $95. Conversely, if both materialize, the bull case of $175 becomes plausible. The report's base case of $135 suggests the stock is slightly overvalued at current levels, supporting a wait-and-see approach.

Thesis delta

The thesis delta is minimal: the new article adds no new information beyond confirming the stock's pullback and Wall Street's cooling sentiment. The positive melanoma data was already incorporated into the report's base, bull, and bear scenarios. Therefore, the WAIT rating and valuation levels remain unchanged.